October 28, 2016 09:57 AM EDT

Another Ramaswamy stunt plays well on Wall Street, Martin Shkreli on shame, and more

Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.

Ramaswamy strikes …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges